|1st October 2020||David F Melcher||3,320||Exercise of derivative||$0.00|
|10th September 2020||Vincent A Forlenza||4.289||Grant/award etc.||$286.39||$1,228.33|
|1st September 2020||Thomas J Spoerel||59||Payment by withholding||$0.00|
|21st July 2020||Catherine M Burzik||1,983||Grant/award etc.||$0.00|
|21st July 2020||Claire Pomeroy||1,983||Grant/award etc.||$0.00|
|10th July 2020||Vincent A Forlenza||11,660||Bona fide gift||$0.00|
|9th July 2020||Patrick Kaltenbach||1,272||Open or private sale||$260.00||$330,720.00|
|30th June 2020||Vincent A Forlenza||21,192||Bona fide gift||$0.00|
|10th June 2020||Vincent A Forlenza||4.422||Grant/award etc.||$277.27||$1,226.09|
|8th June 2020||Timothy M Ring||820||Exercise of derivative||$61.62||$50,524.30|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 6/10.
Becton, Dickinson & Co. is a medical technology company. The firm engages in the development, manufacture and sale of medical supplies, devices, laboratory equipment and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences and BD Interventional.